Home / Top News / Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
AC – Inflammation was Mild and Decreasing over Time in Cohort 3
VC – Inflammation was Mild and Decreasing over Time in Cohort 3
VC – Inflammation was Mild and Decreasing over Time in Cohort 3
Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3
Steroid Eye Drops Post Prophylaxis Decrease over Time in Cohort 3